ABPI and our regional industry groups - andy riley
•Télécharger en tant que PPTX, PDF•
1 j'aime•701 vues
Recommandé
Recommandé
Contenu connexe
Plus de PM Society
Plus de PM Society (20)
Dernier
Dernier (20)
ABPI and our regional industry groups - andy riley
- 1. ABPI and our Regional Industry Groups Andy Riley, Partnerships Manager, Midlands and East
- 3. Real world data and e-health ABPI landscape and policy map Innovation, Health and Wealth value based pricing PPRS Commissioning Reputation UK Competitiveness NHS Partnerships Discovery Development Approval Fair Price Access Uptake Patients Supply Chain Partnerships for research Animal research EU Influence Clinical research Regulatory framework and MHRA Manufacturing and the environment Schools, higher education and skills Intellectual property and patent Pharmacovigilance Patient Group Forum Medicines Optimisation HTA
- 4. Our partnerships for delivery •We have an MOU with the NHS Confederation, ABHI and Medilinks to support the implementation of Innovation, Health and Wealth http://www.nhsconfed.org/priorities/latestnews/Pages/NHS-Confederation- joins-ABPI-ABHI-innovation-project.aspx •This strategic agreement aims to increase the adoption and diffusion of proven technologies in areas of high clinical need to deliver high quality patient outcome and efficiency gains •It includes showcasing best practice for joint working, judged by an independent panel – our first launch event was in February •We work on policy at a national level with a range of organisations, including the DoH, NHS England, NICE, Royal Colleges and others
- 5. Our vision NHS Partnerships Team established in 2012, led by Carol Blount, our director: – Kevin Blakemore, National Manager – Regional Managers: – Di Vegh (South) – Harriet Lewis (North) – Andy Riley (Mids and East) – Karen Thomas (London) – Mike Ringe, Therapy Group Manager – Terry Harrison, consultant – Industry secondee currently Farid Bidgoli from AZ Industry as an integral part of the NHS’s solution to the delivery of better patient outcomes
- 6. NHS Partnership team priorities We are: - Identifying and sharing local NHS issues, organisational and policy changes with member companies - Taking the lead on themes from the Innovation, Health and Wealth and other key priorities, e.g. medicines optimisation - Demonstrating the value of medicines as an opportunity to improve outcomes rather than as a cost pressure to commissioners and providers - Supporting companies in the development of Joint Working projects We aren’t: - Promoting a particular company/ therapy area or product - Trying to improve your market share - Replicating or ‘competing’ with member company field teams - The only way that the NHS can engage with pharma
Notes de l'éditeur
- A full service trade association supporting all research-based biopharmaceutical companiesRecognised by UK&I Governments as the body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirementsWork across the UK – head offices in London, Edinburgh, Cardiff, Belfast – and a field team in EnglandMember companies represent 90% of the value of all medicines used by the NHSCollaborate with the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on EU issues via Brussels and GenevaThe arms length body of the Prescription Medicines Code of Practice Authority (PMCPA) upholds the ABPI Code of Conduct
- ABPIS managing issues where companies can’tA lot of which facilitates what goes on in the previous slidesCreates an environment which ensures the previous channels are openIssues that matter to comapnies and how ABPICompanies can’t address the issues in the same way as ABPI....